Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, in combination with pembrolizumab (KEYTRUDA®; manufactured by …
BERKELEY, Calif., and VANCOUVER, British Columbia, August 11, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has entered into a debt settlement agreement (“Debt Settlement”) with a creditor, that has provided legal services to the Company, to …
BERKELEY, Calif., and VANCOUVER, British Columbia, June 24, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining compositions and methods of developing novel …
Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, with or without a PD-1 …
BERKELEY, Calif., and VANCOUVER, British Columbia, June 9, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a …
Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, showed no serious side effects and resulted in clinical responses in heavily …
BERKELEY, Calif., and VANCOUVER, British Columbia, May 20, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining a novel vaccine platform to selectively …
• New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ASCO 2020 in a Poster Presentation BERKELEY, Calif., and VANCOUVER, British Columbia, May 14, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the publication …
• Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. • BriaCell is currently evaluating a number of business strategies to develop its potential treatments for breast cancer on its own or in partnership. • …
BERKELEY, Calif., and VANCOUVER, British Columbia, April 27, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining the development and use of novel …